4,500 Shares in Danaher Corporation $DHR Purchased by Cantor Fitzgerald Investment Advisors L.P.

Key Points

• Cantor Fitzgerald Investment Advisors acquired 4,500 Danaher shares worth approximately $997,000 in the third quarter. Institutional investors collectively own 79.05% of the company.
• Analysts maintain a positive outlook, with Danaher carrying a consensus “Moderate Buy” rating and an average price target of $235.41. Recent quarterly results beat estimates, with EPS of $1.94 and revenue of $6.26 billion.
• Danaher announced an AI collaboration with NVIDIA aimed at advancing autonomous science and drug discovery, while preparing to launch its first AI-powered autonomous laboratory at commercial scale in early 2027.

Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,500 shares of the conglomerate's stock, valued at approximately $997,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new stake in Danaher in the 2nd quarter valued at $3,807,000. Puzo Michael J purchased a new position in Danaher in the second quarter valued at about $8,624,000. Madison Asset Management LLC acquired a new position in shares of Danaher during the second quarter worth about $85,451,000. First Nebraska Trust Co acquired a new position in shares of Danaher during the second quarter worth about $14,106,000. Finally, Colton Groome Financial Advisors LLC purchased a new stake in shares of Danaher in the third quarter worth about $592,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wells Fargo & Company decreased their price target on Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a report on Wednesday, July 22nd. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a research note on Monday, October 5th. Guggenheim increased their price target on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a report on Thursday, October 1st. The Goldman Sachs Group raised their price objective on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a research note on Monday, September 21st. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average price target of $235.41.

Danaher Stock Performance

Shares of DHR stock opened at $231.52 on Friday. The company's 50-day simple moving average is $213.55 and its 200-day simple moving average is $195.74. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company posted $0.77 EPS. The business's revenue was up 5.5% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher's payout ratio is presently 28.42%.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.